Long-acting antipsychotics and neurocognitive functions in schizophrenia Review article
Article Sidebar
Published:
Sep 30, 2013
Keywords:
schizophrenia, cognitive functions, long-acting antipsychotics
Main Article Content
Abstract
Neurocognitive impairment is considered to be a core symptom in schizophrenia. It may occur in prodromal period, may persist or even get worse during the course of the disease and influence patients social functioning, disease insight and treatment adherence. Different cognitive domains can be affected, amongst them executive functions, which are connected with frontal dysfunction. Second generation antipsychotics seem to ameliorate neurocognitive functioning, however, the effect size is rather small or moderate. The improvement may be related to symptomatic change, practice effect or even neuroprotective properties of these agents. Long-acting second generation antipsychotics have not been extensively investigated, initial reports seem to confirm their advantage over oral formulation. It may reflect treatment adherence improvement, lower doses of antipsychotics used, lower risk of extrapyramidal symptoms and lower frequency of anticholinergic agents using.
Article Details
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Galińska B, Szulc A, Tarasow E, Kubas B, Dzienis W, SiergiejczykvL, Czernikiewicz A, Walecki J. Relationship between front alvN-acetylaspartate and cognitive deficits in first-episode schizophrenia.vMed Sci Monit 2007; 13 (Suppl. 1): 11-16.
2. Borkowska A. Znaczenie zaburzeń funkcji poznawczych i możliwościvich oceny w zaburzeniach psychicznych. Psychiatriavw Praktyce Medycznej 2009; 2: 30-40.
3. O’Grada C, Dinan T. Executive function in schizophrenia: whatvimpact do antipsychotics have? Hum Psychopharmacol ClinvExp 2007; 22: 397-406.
4. Riedel M, Schennach-Wolf R, Musil R, Dehning S, Cerovecki A,vOpgen-Rhein M, Matz J, Seemuller F, Obermeier M, Engel RR,vMuller N, Moller H-J, Spellmann I. Neurocognition and its influencingvfactors in the treatment of schizophrenia – effectsvof aripiprazole, olanzapine, quetiapine and risperidone. HumvPsychopharmacol Clin Exp 2010; 25: 116-25.
5. Hill SR. Effect of second-generation antipsychotics on cognition:vcurrent issues and future challenges. Expert Rev Neurotherv2010; 10: 43-57.
6. Burdick KE, Gopin CB, Malhotra AK. Pharmacogenetic Approachesvto Cognitive Enhancement in Schizophrenia. Harv RevvPsychiatry 2011; 19: 102-108.
7. Minzenbrg MJ, Carter CS. Developing treatments for impairedvcognition in schizophrenia. Trends in Cognitive Sciences 2012;v16: 36-42.
8. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, GoldvJM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP,vSwartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK,vLieberman JA; CATIE Investigators. Neurocognitive WorkingvGroup. Arch Gen Psychiatry 2007; 64: 633-47.
9. Penn DL, Keefe RS, Davis SM, Meyer PS, Perkins DO, LosardoD, Lieberman JA. The Effects of Antipsychotic Medication onvEmotion Perception in Patients with Chronic Schizophrenia invthe CATIE Trial. Schizophr Res 2009; 115: 17-23.
10. Kucharska-Pietura K, Tylec A, Czernikiewicz A, Mortimer A.vAttentional and emotional functioning in schizophrenia patientsvtreated with conventional and atypical antipsychoticvdrugs. Med Sci Monit 2012; 18: CR44-9.
11. Kucharska-Pietura K, Mortimer A. Can Antipsychotics ImprovevSocial Cognition in Patients with Schizophrenia? CNS Drugsv2013; 27: 335-43.
12. Guo X, Zhai J, Wei O, Twamley EW, Jin H, Fang M, Hu M, ZhaovJ; For the Early-stage Schizophrenia Outcome Study (EOS) investigators.vNeurocognitive effects of firs- and second-generationvantipsychotic drugs in early-stage schizophrenia: A naturalisticv12-month follow-up study. Neurosci Lett 2011; 503:v141-6.
13. Zhang J-P, Gallego JA, Robinson DG, Malhotra AK, Kane JMK,vCorrell CU. Efficacy and Safety of Individual Second-Generationvvs First-Generation Antipsychotics in First Episode Psychosis:vA Systematic Review and Meta-analysis. Int J Neuropsychopharmacolv2013; 16: 1205-18.
14. Hori H, Yoshimura R, Katsuki A, Hayashi K, Ikenouchi-Sugita A,vUmene-Nakano W, Nakamura J. The cognitive profile of aripiprazolevdiffers from that of other atypical antipsychotics invschizophrenia patients J Psych Res 2012; 46: 757-61.
15. Cuesta MJ, de Jalon EG, Campos MS, Peralta V. Cognitive effectivenessvof olanzapine and risperidone in first-episode psychosis.vBr J Psychiatry 2009; 194: 439-45.
16. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoyvJP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidonevon neurocognitive function in early psychosis: a randomized,vdouble-blind 52-week comparison. Am J Psychiatryv2007; 164: 1061-71.
17. Frazier JA, Giuliano AJ, Johnson JL, Yakutis L, Youngstrom EA,vBreiger D, Sikich L, Findling RL, McClellan J, Hamer RM, VitiellovB, Lieberman JA, Hooper SR. Neurocognitive Outcomes in thevTreatment of Early-Onset Schizophrenia Spectrum DisordersvStudy. J Am Acad Child Adolesc Psychiatry 2012; 51: 496-505.
18. Remberk B, Namysłowska I, Rybakowski F. Cognition and communicationvdysfunctions in early-onset schizophrenia: Effectvof risperidone. Prog Neuropsychopharmacol Biol Psychiatryv2012; 39: 348-54.
19. Robles O, Zabala A, Bombin I, Parellada M, Moreno D, Ruiz-Sanchez A, Arango C. Cognitive Efficacy of Quetiapine and Olanzapine in Early-Onset First-Episode Psychosis. Schizophr Bull 2011; 37: 405-15.
20. Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res 2011; 127: 188-94.
21. Nikiforuk A, Popik P. Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats. Psychopharmacology 2012; 220: 65-74.
22. Nikiforuk A. Quetiapine ameliorates stress-induced cognitive inflexibility in rats. Neuropharmacology 2013; 64: 357-364.
23. Elsworth JD, Groman S, Jentsch JD, Valles R, Shahid M, Wong E, Marston H, Roth RH. Asenapine Effects on Cognitive and Monoamine Dysfunction Elicited by Subchronic Phencyclidine Administartion. Neuropharmacology 2012; 62: 1442-52.
24. Russo E, Citraro R, Davoli A, Gallelli L, Di Paola ED, De Sarro G. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology 2013; 64: 371-9.
25. Tuninger E, Levander S. Neuropsychological impairment in patients treated with depot neuroleptics: a longitudinal study. Acta Psychiatr Scand 2001; 104(Suppl. 408); 75-80.
26. Kim S-W, Shin I-S, Kim J-M, Lee S-H, Lee Y-H, Yang S-J, Yoon J-S. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Hum Psychopharmacol Clin Exp 2009; 24: 565-73.
27. Pandina GJ, Zhu Y, Cornblatt B. Cognitive function with longterm risperidone in children and adolescents with disruptive behavior disorder. J Child Adolesc Psychopharmacol 2009; 19: 749-56.
28. Lindenmayer J-P, Khan A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res 2011; 125: 267-277.
29. Suzuki H, Gen K. The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. Hum Psychopharmacol Clin Exp 2012; 27: 470-5.
30. Suzuki H, Gen K. The influence of switching from oral risperidone to risperidone long-acting injection on the clinical symptoms and cognitive function schizophrenia. Ther Adv Psychopharmacol 2012; 2: 23-9.
31. Keefe RSE, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Muthy A, Sovel M, Li C, Goldman R. Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo Controlled Trial. Neuropsychopharmacology 2008; 33: 1217-28.
32. Szulc A, Waszkiewicz N, Rudzki L. Wpływ leków antypsychotycznych na zmiany strukturalne mózgu – przegląd badań neuroobrazowych. Farm Psych Neurol 2012; 3-4: 127-34.
33. Szulc A, Galińska-Skok B, Waszkiewicz N, Bibułowicz D, Konarzewska B, Tarasow E. Proton magnetic resonance spectroscopy changes after antipsychotic treatment. Curr Med Chemistry 2013; 20: 414-27.
34. Bartzokis G, Lu PH, Raven EP, Amar CA, Detoe NR, Couvrette AJ, Mintz J, Ventura J, Casaus LR, Luo JS, Subotnik KL, Nuechterlein KH. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr Res 2012; 140: 122-8.
2. Borkowska A. Znaczenie zaburzeń funkcji poznawczych i możliwościvich oceny w zaburzeniach psychicznych. Psychiatriavw Praktyce Medycznej 2009; 2: 30-40.
3. O’Grada C, Dinan T. Executive function in schizophrenia: whatvimpact do antipsychotics have? Hum Psychopharmacol ClinvExp 2007; 22: 397-406.
4. Riedel M, Schennach-Wolf R, Musil R, Dehning S, Cerovecki A,vOpgen-Rhein M, Matz J, Seemuller F, Obermeier M, Engel RR,vMuller N, Moller H-J, Spellmann I. Neurocognition and its influencingvfactors in the treatment of schizophrenia – effectsvof aripiprazole, olanzapine, quetiapine and risperidone. HumvPsychopharmacol Clin Exp 2010; 25: 116-25.
5. Hill SR. Effect of second-generation antipsychotics on cognition:vcurrent issues and future challenges. Expert Rev Neurotherv2010; 10: 43-57.
6. Burdick KE, Gopin CB, Malhotra AK. Pharmacogenetic Approachesvto Cognitive Enhancement in Schizophrenia. Harv RevvPsychiatry 2011; 19: 102-108.
7. Minzenbrg MJ, Carter CS. Developing treatments for impairedvcognition in schizophrenia. Trends in Cognitive Sciences 2012;v16: 36-42.
8. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, GoldvJM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP,vSwartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK,vLieberman JA; CATIE Investigators. Neurocognitive WorkingvGroup. Arch Gen Psychiatry 2007; 64: 633-47.
9. Penn DL, Keefe RS, Davis SM, Meyer PS, Perkins DO, LosardoD, Lieberman JA. The Effects of Antipsychotic Medication onvEmotion Perception in Patients with Chronic Schizophrenia invthe CATIE Trial. Schizophr Res 2009; 115: 17-23.
10. Kucharska-Pietura K, Tylec A, Czernikiewicz A, Mortimer A.vAttentional and emotional functioning in schizophrenia patientsvtreated with conventional and atypical antipsychoticvdrugs. Med Sci Monit 2012; 18: CR44-9.
11. Kucharska-Pietura K, Mortimer A. Can Antipsychotics ImprovevSocial Cognition in Patients with Schizophrenia? CNS Drugsv2013; 27: 335-43.
12. Guo X, Zhai J, Wei O, Twamley EW, Jin H, Fang M, Hu M, ZhaovJ; For the Early-stage Schizophrenia Outcome Study (EOS) investigators.vNeurocognitive effects of firs- and second-generationvantipsychotic drugs in early-stage schizophrenia: A naturalisticv12-month follow-up study. Neurosci Lett 2011; 503:v141-6.
13. Zhang J-P, Gallego JA, Robinson DG, Malhotra AK, Kane JMK,vCorrell CU. Efficacy and Safety of Individual Second-Generationvvs First-Generation Antipsychotics in First Episode Psychosis:vA Systematic Review and Meta-analysis. Int J Neuropsychopharmacolv2013; 16: 1205-18.
14. Hori H, Yoshimura R, Katsuki A, Hayashi K, Ikenouchi-Sugita A,vUmene-Nakano W, Nakamura J. The cognitive profile of aripiprazolevdiffers from that of other atypical antipsychotics invschizophrenia patients J Psych Res 2012; 46: 757-61.
15. Cuesta MJ, de Jalon EG, Campos MS, Peralta V. Cognitive effectivenessvof olanzapine and risperidone in first-episode psychosis.vBr J Psychiatry 2009; 194: 439-45.
16. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoyvJP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidonevon neurocognitive function in early psychosis: a randomized,vdouble-blind 52-week comparison. Am J Psychiatryv2007; 164: 1061-71.
17. Frazier JA, Giuliano AJ, Johnson JL, Yakutis L, Youngstrom EA,vBreiger D, Sikich L, Findling RL, McClellan J, Hamer RM, VitiellovB, Lieberman JA, Hooper SR. Neurocognitive Outcomes in thevTreatment of Early-Onset Schizophrenia Spectrum DisordersvStudy. J Am Acad Child Adolesc Psychiatry 2012; 51: 496-505.
18. Remberk B, Namysłowska I, Rybakowski F. Cognition and communicationvdysfunctions in early-onset schizophrenia: Effectvof risperidone. Prog Neuropsychopharmacol Biol Psychiatryv2012; 39: 348-54.
19. Robles O, Zabala A, Bombin I, Parellada M, Moreno D, Ruiz-Sanchez A, Arango C. Cognitive Efficacy of Quetiapine and Olanzapine in Early-Onset First-Episode Psychosis. Schizophr Bull 2011; 37: 405-15.
20. Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res 2011; 127: 188-94.
21. Nikiforuk A, Popik P. Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats. Psychopharmacology 2012; 220: 65-74.
22. Nikiforuk A. Quetiapine ameliorates stress-induced cognitive inflexibility in rats. Neuropharmacology 2013; 64: 357-364.
23. Elsworth JD, Groman S, Jentsch JD, Valles R, Shahid M, Wong E, Marston H, Roth RH. Asenapine Effects on Cognitive and Monoamine Dysfunction Elicited by Subchronic Phencyclidine Administartion. Neuropharmacology 2012; 62: 1442-52.
24. Russo E, Citraro R, Davoli A, Gallelli L, Di Paola ED, De Sarro G. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology 2013; 64: 371-9.
25. Tuninger E, Levander S. Neuropsychological impairment in patients treated with depot neuroleptics: a longitudinal study. Acta Psychiatr Scand 2001; 104(Suppl. 408); 75-80.
26. Kim S-W, Shin I-S, Kim J-M, Lee S-H, Lee Y-H, Yang S-J, Yoon J-S. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Hum Psychopharmacol Clin Exp 2009; 24: 565-73.
27. Pandina GJ, Zhu Y, Cornblatt B. Cognitive function with longterm risperidone in children and adolescents with disruptive behavior disorder. J Child Adolesc Psychopharmacol 2009; 19: 749-56.
28. Lindenmayer J-P, Khan A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res 2011; 125: 267-277.
29. Suzuki H, Gen K. The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. Hum Psychopharmacol Clin Exp 2012; 27: 470-5.
30. Suzuki H, Gen K. The influence of switching from oral risperidone to risperidone long-acting injection on the clinical symptoms and cognitive function schizophrenia. Ther Adv Psychopharmacol 2012; 2: 23-9.
31. Keefe RSE, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Muthy A, Sovel M, Li C, Goldman R. Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo Controlled Trial. Neuropsychopharmacology 2008; 33: 1217-28.
32. Szulc A, Waszkiewicz N, Rudzki L. Wpływ leków antypsychotycznych na zmiany strukturalne mózgu – przegląd badań neuroobrazowych. Farm Psych Neurol 2012; 3-4: 127-34.
33. Szulc A, Galińska-Skok B, Waszkiewicz N, Bibułowicz D, Konarzewska B, Tarasow E. Proton magnetic resonance spectroscopy changes after antipsychotic treatment. Curr Med Chemistry 2013; 20: 414-27.
34. Bartzokis G, Lu PH, Raven EP, Amar CA, Detoe NR, Couvrette AJ, Mintz J, Ventura J, Casaus LR, Luo JS, Subotnik KL, Nuechterlein KH. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr Res 2012; 140: 122-8.